Shares of Kite Pharma, Inc. (KITE) popped nearly +16% today, after
the company announced acquisition of a privately held Netherlands-based biotechnology company, T-Cell Factory B.V. This may not have been the only reason. Juno Therapeutics (JUNO) said today that it expects to have 10 product candidates in clinical development directed at six different cancer-associated antigens. Other stocks in the same space, such as BLCM and BLUE also soared. BLCM was up more than +6% and BLUE gained almost +5%.
We picked up some KITE April calls this morning and already locked in some nice intraday profits:
Earlier this week we also locked nice profits on JAZZ and MYL. JAZZ calls garnered +59.78% profit, and MYL gave us a +120.62% gain:
My Happy Trading portfolio is a nice product for the biotech stocks. This portfolio is geared towards “leisure” traders/investors. In this product, I trade mainly options that are at least one month out in due dates. Since it’s difficult to know when these biotech stocks will move, although they seem to be moving quite a bit recently, and the options are not cheap, it is good to give ourselves sometime for the trades to work out.
To subscribe to this product, please visit the product page by
Good night and